Leukemia Research
Volume 25, Issue 9 , Pages 801-811 , 1 September 2001

Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway

Received 1 June 2000 ,Accepted 20 January 2001.

References 

  1. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845–1853
  2. O'Connor R. Survival factors and apoptosis. In:  Scheper T editors. Advances in biochemical engineering/biotechnology. 62:Heidelberg: Springer; 1998;p. 137–166
  3. O'Gorman DM, McKenna SL, McGahon AJ, Knox KA, Cotter TG. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia. 2000;14:602–611
  4. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell. 1997;88:435–437
  5. Krammer PH. CD95(APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 1999;71:163–210
  6. Posovszky C, Friesen C, Herr I, Debatin KM. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia. 1999;13:400–409
  7. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 1996;2:574–577
  8. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997;57:3823–3829
  9. Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitises androgen-independent prostate cancer cells to Fas-induced apoptosis. Br. J. Cancer. 2000;82:1827–1834
  10. Friesen C, Fulda S, Debatin KM. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells. Leukemia. 1997;11:1833–1841
  11. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κ-B and AP-1. Mol. Cell. 1998;1:543–551
  12. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 1997;99:403–413
  13. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell. Mol. Life Sci. 1999;55:1230–1254
  14. Seimiya H, Mashima T, Toho M, Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. J. Biol. Chem. 1997;272:4631–4636
  15. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell. Biol. 1999;19:751–763
  16. Hausler P, Papoff G, Eramo A, Reif K, Cantrell DA, Ruberti G. Protection of CD95-mediated apoptosis by activation of phosphatidylinositide 3-kinase and protein kinase B. Eur. J. Immunol. 1998;28:57–69
  17. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54:713–733
  18. Gorman A, McCarthy J, Finucane D, Reville W, Cotter TG. Morphological assessment of apoptosis. In:  Cotter TG,  Martin SJ editor. Techniques in apoptosis, a user's guide. London: Portland Press; 1996;p. 1–20
  19. Hoffbrand AV, Pettit JE. In: Acute leukaemias: essential haematology. 3rd ed.. Oxford: Blackwell Scientific; 1993;p. 209–231
  20. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 1997;22:355–358
  21. Colotta F, Polentarutti N, Sironi M, Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J. Biol. Chem. 1992;267:18278–18283
  22. Lee HY, Walsh GL, Dawson MI, Hong WK, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways. J. Biol. Chem. 1998;273:7066–7071
  23. Franke TF, Cantley LC. Apoptosis. A Bad kinase makes good. Nature. 1997;390:116–117
  24. Low W, Smith A, Ashworth A, Collins M. JNK activation is not required for Fas-mediated apoptosis. Oncogene. 1999;18:3737–3741
  25. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318–1321
  26. Fujita E, Kouroku Y, Miho Y, Tsukahara T, Ishiura S, Momoi T. Wortmannin enhances activation of CPP32 (Caspase-3) induced by TNF or anti-Fas. Cell Death Differ. 1998;5:289–297
  27. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997;16:2794–2804
  28. Romashkova JA, Makarov SS. NF-κB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86–90
  29. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase. Nature. 1999;401:82–85
  30. Foo SY, Nolan GP. NF-κB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet. 1999;15:229–235
  31. Wang CY, Guttridge DC, Mayo MW, Baldwin AS. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 1999;19:5923–5929
  32. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. USA. 1999;96:9136–9141
  33. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, Ballard DW. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl. Acad. Sci. USA. 1997;94:10057–10062
  34. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 1996;274:784–787
  35. Kuhnel F, Zender L, Paul Y, Tietze MK, Trautwein C, Manns M, et al. NF-κB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 2000;275:6421–6427
  36. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  37. Byrne JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br. J. Haematol. 1998;100:256–264
  38. Collard JG, van Beek WP, Janssen JW, Schijven JF. Transfection by human oncogenes: concomitant induction of tumorigenicity and tumor-associated membrane alterations. Int. J. Cancer. 1985;35:207–213
  39. Hall A, Marshall CJ, Spurr NK, Weiss RA. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature. 1983;303:396–400
  40. Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 1994;4:798–806
  41. Beaupre DM, Kurzrock R. RAS inhibitors in hematologic cancers: biologic considerations and clinical applications. Invest. New Drugs. 1999;17:137–143

PII: S0145-2126(01)00024-8

Leukemia Research
Volume 25, Issue 9 , Pages 801-811 , 1 September 2001

Article Tools

* Image Usage & Resolution